Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, together with standard chemotherapies form the mainstay of tumour targeted therapy for metastatic RAS/BRAF wild-type (WT) CRC, whereas improvements in responses and survival have been found with the BRAF kinase inhibitor encorafenib when combined with cetuximab in BRAF mutant (MT) metastatic CRC (mCRC) [3–5]. The gene discussed is BRAF; the disease is neoplasm.